Verified news and analysis on AI pharma — clinical milestones, financing, partnerships, and regulation. Updated regularly.
AI Native drug discovery company AIPher has announced the completion of a 100 million yuan angel round financing. The funding will support the continuous R&D of its DrugCLIP foundation model and PharmAgents intelligent agent engine, alongside the advancement of innovative drug pipelines.
AI-driven drug discovery company Insilico Medicine has announced a new investment led by Aramco-backed Prosperity7 Ventures. This latest funding brings the company's total Series D financing to $95 million, further supporting its AI-powered drug development pipeline.
China has approved its first AI-assisted 'Class 1' innovative drug, marking a significant milestone in the country's pharmaceutical sector. The COVID-19 treatment took just three and a half years from the discovery of the drug candidate to the completion of clinical trials.
Bristol-Myers Squibb has partnered with AI company Anthropic to accelerate and enhance its drug discovery processes. This strategic collaboration aims to leverage advanced artificial intelligence to supercharge pharmaceutical innovation and development.
Faro AI has secured $37.3 million in funding to expand its AI agents that automate clinical development processes. The round was co-led by Merck's venture fund, highlighting growing pharmaceutical industry interest in AI-driven clinical trial efficiency.
Insilico Medicine has secured $60 million in Series D funding to advance its drug discovery pipeline. The company will also use the capital to launch an AI-powered drug discovery robotics laboratory to accelerate its research and development processes.
A company has successfully utilized off-the-shelf AI tools like ChatGPT and Gemini to assist in designing a new drug candidate. This highlights the growing accessibility and practical application of large language models in medicinal chemistry and drug discovery.
Commercial platforms are now extending generative AI capabilities to smaller biotechnology companies and academic researchers. These platforms provide access to models trained on decades of pharmaceutical data to significantly improve hit identification in drug discovery.
Faro has raised $37.3 million in Series B funding co-led by Merck Global Health Innovation Fund and S32 to scale its agentic AI platform. The investment will support the expansion of AI-driven automation across clinical development processes.
A recent development highlights a significant proof point for AI-led biology, where an AI-discovered neuroscience drug target was successfully acquired by a pharmaceutical company. This transaction underscores the growing validation of AI in identifying novel therapeutic targets.